logo
Is JPMorgan US Rsrch Enhanc Equity A (JDEAX) a Strong Mutual Fund Pick Right Now?

Is JPMorgan US Rsrch Enhanc Equity A (JDEAX) a Strong Mutual Fund Pick Right Now?

Yahoo3 days ago
If you have been looking for Large Cap Blend funds, a place to start could be JPMorgan US Rsrch Enhanc Equity A (JDEAX). JDEAX carries a Zacks Mutual Fund Rank of 1 (Strong Buy), which is based on various forecasting factors like size, cost, and past performance.
Objective
We note that JDEAX is a Large Cap Blend option, an area loaded with different options. More often than not, Large Cap Blend mutual funds invest in companies with a market cap of over $10 billion. Buying stakes in bigger companies offer these funds more stability, and are well-suited for investors with a " buy and hold " mindset. Additionally, blended funds mix large, more established firms into their portfolios, giving investors exposure to value and growth opportunities.
History of Fund/Manager
JDEAX finds itself in the J.P. Morgan family, based out of Boston, MA. Since JPMorgan US Rsrch Enhanc Equity A made its debut in January of 1997, JDEAX has garnered more than $572.98 million in assets. The fund is currently managed by Raffaele Zingone who has been in charge of the fund since July of 2002.
Performance
Investors naturally seek funds with strong performance. This fund in particular has delivered a 5-year annualized total return of 16.92%, and is in the top third among its category peers. But if you are looking for a shorter time frame, it is also worth looking at its 3-year annualized total return of 19.58%, which places it in the top third during this time-frame.
It is important to note that the product's returns may not reflect all its expenses. Any fees not reflected would lower the returns. Total returns do not reflect the fund's [%] sale charge. If sales charges were included, total returns would have been lower.
When looking at a fund's performance, it is also important to note the standard deviation of the returns. The lower the standard deviation, the less volatility the fund experiences. Compared to the category average of 14.79%, the standard deviation of JDEAX over the past three years is 15.65%. Over the past 5 years, the standard deviation of the fund is 16.37% compared to the category average of 14.33%. This makes the fund more volatile than its peers over the past half-decade.
Risk Factors
Investors should note that the fund has a 5-year beta of 1, which means it is hypothetically as volatile as the market at large. Another factor to consider is alpha, as it reflects a portfolio's performance on a risk-adjusted basis relative to a benchmark-in this case, the S&P 500. With a positive alpha of 0.26, managers in this portfolio are skilled in picking securities that generate better-than-benchmark returns.
Holdings
Examining the equity holdings of a mutual fund is also a valuable exercise. This can show us how the manager is applying their stated methodology, as well as if there are any inherent biases in their approach. For this particular fund, the focus is largely on equities that are traded in the United States.
As of the last filing date, the mutual fund has 90.42% of its assets in stocks, and these companies have an average market capitalization of $444.91 billion. The fund has the heaviest exposure to the following market sectors:
Technology
Finance
Turnover is 39%, which means, on average, the fund makes fewer trades than the average comparable fund.
Expenses
As competition heats up in the mutual fund market, costs become increasingly important. Compared to its otherwise identical counterpart, a low-cost product will be an outperformer, all other things being equal. Thus, taking a closer look at cost-related metrics is vital for investors. In terms of fees, JDEAX is a load fund. It has an expense ratio of 0.60% compared to the category average of 0.87%. Looking at the fund from a cost perspective, JDEAX is actually cheaper than its peers.
Investors should also note that the minimum initial investment for the product is $1,000 and that each subsequent investment needs to be at $50
Fees charged by investment advisors have not been taken into considiration. Returns would be less if those were included.
Bottom Line
Overall, JPMorgan US Rsrch Enhanc Equity A ( JDEAX ) has a high Zacks Mutual Fund rank, and in conjunction with its comparatively strong performance, average downside risk, and lower fees, JPMorgan US Rsrch Enhanc Equity A ( JDEAX ) looks like a good potential choice for investors right now.
Want even more information about JDEAX? Then go over to Zacks.com and check out our mutual fund comparison tool, and all of the other great features that we have to help you with your mutual fund analysis for additional information. And don't forget, Zacks has all of your needs covered on the equity side too! Make sure to check out Zacks.com for more information on our screening capabilities, Rank, and all our articles as well.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Get Your Free (JDEAX): Fund Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sarepta Therapeutics: Why Is SRPT Stock Crashing?
Sarepta Therapeutics: Why Is SRPT Stock Crashing?

Forbes

timea few seconds ago

  • Forbes

Sarepta Therapeutics: Why Is SRPT Stock Crashing?

CANADA - 2025/06/08: In this photo illustration, the Sarepta Therapeutics logo is seen displayed on ... More a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) Sarepta Therapeutics has plunged to new lows below $13, down over 35% in recent trading, after rejecting the FDA's request to voluntarily halt all shipments of Elevidys following a third death tied to the gene therapy. Just days after our previous analyses highlighted the company's apparent undervaluation following its restructuring, its defiant stance has now triggered fresh investor concerns, validating the regulatory risks associated with biotech stocks. The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns. With Elevidys generating 43% of Sarepta's total revenues and holding traditional approval since June 2024 for ambulatory patients, any regulatory challenge poses existential threats to the company. FDA Commissioner Marty Makary's statement that he's "taking a hard look" at whether Elevidys should remain on the market suggests potential forced withdrawal if voluntary compliance fails. The recent $400 million restructuring cost savings appear insufficient against potential revenue loss from broader market restrictions. Sarepta's confrontational approach toward federal regulators is creating unprecedented uncertainty, even for biotech investors who typically have a high tolerance for risk. This unwillingness to proactively address safety concerns demonstrates poor risk management, especially at a time when regulatory goodwill is crucial. Situations like this underscore our consistent message about the inherent risks of investing in single stocks and highlight why professionally managed portfolios are often a better choice. In fact, regulatory risk is just a small part of the risk assessment framework we apply while constructing the Trefis High Quality (HQ) Portfolio which, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride as evident in HQ Portfolio performance metrics.

Buy Or Sell Philip Morris Stock Ahead Of Its Q2 Earnings?
Buy Or Sell Philip Morris Stock Ahead Of Its Q2 Earnings?

Forbes

timea few seconds ago

  • Forbes

Buy Or Sell Philip Morris Stock Ahead Of Its Q2 Earnings?

AFP PHOTO/Timothy A. CLARY Philip Morris International (NYSE:PM) is set to disclose its earnings on Tuesday, July 22, 2025. Reviewing the data from the past five years, Philip Morris stock has demonstrated positive one-day returns following earnings reports in 60% of cases. The median positive return recorded was 3.2%, with the highest one-day positive return reaching 10.9%. For traders focusing on events, while actual results compared to consensus and expectations are critical, recognizing these historical trends can offer a strategic edge. Two key strategies may be utilized: Experts expect Philip Morris to report earnings of $1.86 per share on revenues of $10.33 billion. These projections surpass the results from the same quarter last year, which reported earnings of $1.59 per share on sales of $9.47 billion. From a fundamental viewpoint, the firm currently possesses a market capitalization of $285 billion. In the previous twelve months, Philip Morris generated $38 billion in revenue, attaining $14 billion in operating profits and a net income of $7.6 billion. That said, if you're looking for upside with less volatility than individual stocks, the Trefis High Quality portfolio offers an option — having outperformed the S&P 500 and produced returns greater than 91% since its inception. Additionally, check out – RCAT Stock To $25? Philip Morris International's Historical Probabilities Of Positive Post-Earnings Returns Here are some insights on one-day (1D) post-earnings returns: Further data regarding observed 5-Day (5D) and 21-Day (21D) returns following earnings is summarized along with the statistics in the table below. 5-Day (5D) and 21-Day (21D) returns following earnings Relationship Between 1D, 5D, and 21D Historical Returns A relatively less risky strategy (though ineffective if the correlation is weak) is to comprehend the correlation between short-term and medium-term returns after earnings, identify a pair that has the highest correlation, and execute the suitable trade. For instance, if 1D and 5D display the highest correlation, a trader can take a "long" position for the next 5 days if the 1D post-earnings return is positive. Below is some correlation data based on the 5-year and 3-year (more recent) history. Note that the correlation 1D_5D refers to the relationship between 1D post-earnings returns and subsequent 5D returns. Correlation Between 1D, 5D, and 21D Historical Returns Discover more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (a combination of all three, the S&P 500, S&P mid-cap, and Russell 2000), generating strong returns for investors. Additionally, if you seek upside with a smoother experience than an individual stock like Philip Morris International, consider the High Quality portfolio, which has outperformed the S&P and achieved >91% returns since its inception. Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates

Should You Buy Coca-Cola Stock Ahead Of Its Upcoming Earnings?
Should You Buy Coca-Cola Stock Ahead Of Its Upcoming Earnings?

Forbes

timea few seconds ago

  • Forbes

Should You Buy Coca-Cola Stock Ahead Of Its Upcoming Earnings?

Photo byCoca-Cola (NYSE:KO) is set to release its earnings on Tuesday, July 22, 2025. Analyzing the past five years, Coca-Cola stock has shown a pattern of positive one-day returns after earnings announcements, occurring in 72% of cases. The median positive return recorded was 1.4%, with a maximum one-day positive return of 4.7%. For traders focused on events, while the actual results against consensus and expectations are significant, recognizing these historical trends can provide a strategic edge. There are two main strategies worth considering: Analysts predict Coca-Cola will report earnings of $0.84 per share on revenues of $12.55 billion. This is in comparison to the earnings of $0.84 per share on revenues of $12.31 billion in the same quarter last year. From a fundamental viewpoint, the company currently has a market capitalization of $298 billion. Over the past twelve months, Coca-Cola generated $47 billion in revenue, recording $14 billion in operating profits and a net income of $11 billion. That being said, if you are looking for upside with lower volatility than individual stocks, the Trefis High Quality portfolio provides an alternative — it has outperformed the S&P 500 and achieved returns exceeding 91% since its inception. Meanwhile, see – RCAT Stock To $25? Coca-Cola's Historical Odds Of Positive Post-Earnings Return Here are some insights regarding one-day (1D) post-earnings returns: Additional information regarding the observed 5-Day (5D) and 21-Day (21D) returns post earnings is compiled alongside the statistics in the table below. KO 1D, 5D, and 21D Post Earnings Return Correlation Between 1D, 5D, and 21D Historical Returns A generally less risky approach (though it may be ineffective if the correlation is weak) is to analyze the correlation between short-term and medium-term returns after earnings, identify a pair with the highest correlation, and execute the corresponding trade. For instance, if 1D and 5D exhibit the strongest correlation, a trader could go "long" for the next 5 days if the 1D post-earnings return is positive. Below is some correlation data based on 5-year and 3-year (more recent) history. Note that the correlation 1D_5D indicates the correlation between 1D post-earnings returns and the subsequently recorded 5D returns. KO Correlation Between 1D, 5D and 21D Historical Returns Is There Any Correlation With Peer Earnings? At times, the performance of peers can affect the stock reaction following earnings. In fact, the pricing-in can begin prior to the earnings being announced. Below is some historical data regarding the post-earnings performance of Coca-Cola stock compared to the stock performance of peers that reported earnings just before Coca-Cola. For a fair comparison, peer stock returns also reflect post-earnings one-day (1D) returns. KO Correlation With Peer Earnings Discover more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (a combination of the S&P 500, S&P mid-cap, and Russell 2000), providing strong returns for investors. Additionally, if you are interested in upside with a smoother experience than an individual stock like Coca-Cola, explore the High Quality portfolio, which has outperformed the S&P and achieved >91% returns since it began. Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store